In the first report1, which concerned an outbreak on a busy competition yard after the introduction of a new horse without an isolation period or pre-movement blood ELISA screening for recent S. equi exposure, no horses developed signs of strangles after the second vaccination with Strangvac was administered.
In the second report2 strangles was confirmed in three unvaccinated and unwell horses and 17 healthy horses on the same yard were subsequently vaccinated with Strangvac.
Blood samples in this group of vaccinated horses demonstrated that over half had recent exposure to S. equi, despite which, none of them developed strangles.
Bex Glasgow, veterinary surgeon and equine veterinary advisor at Dechra said: “Strangles vaccination, alongside good biosecurity measures, are essential tools in disease prevention and recent studies have also demonstrated its protective effect during outbreak situations.”
Strangles Awareness Week, which is supported by Dechra, takes place from 4 to 10 May 2026.
References
The new hydrolysed diet contains hydrolysed proteins, AuraGuard, fibres and Zeolite.
Dechra says the new formula featured in both diets offers superior palatability and works in a multi-action way with support of the gut-kidney axis to help optimise protein absorption and maintenance of muscle mass, gut barrier integrity and a healthy microbiome, while lowering uremic toxins in the blood.
The company says both diets control levels of protein, phosphorus and sodium and offer high levels of the Omega-3 fatty acids EPA and DHA.
Becky Morris, marketing manager at Dechra, said: "Chronic kidney disease is a lifelong progressive disease in dogs and cats, and nutrition is an important part of management to help slow disease progression, improve quality of life and reduce the risk of secondary complications.
"Our new and updated highly palatable Specific Heart & Kidney Support diets will help keep dogs and cats in good condition, prolonging the progression of the disease and the lifespan of the pet."
https://www.specific-diets.co.uk
The course, which has been produced as part of Dechra's collaboration with Not One More Vet, is presented by vets who specialise in mental health counselling.
The four new topics are: client communication: the human side of veterinary medicine; professional identity development for students and recent graduates; executive function management and mental health; and the science of mindfulness.
https://academy.dechra.com/learn/catalog/view/502
DuOtic contains terbinafine, an antifungal, and betamethasone acetate, a corticosteroid.
One tube is administered per affected ear, with a second dose given after seven days.
The maximum clinical response may be seen up to 21 days after the second dose
The product was unveiled earlier this year at an event attended by around 80 vets and nurses, where speakers discussed the importance of a holistic approach to otitis externa and the need for judicious antibiotic use.
Speaking at the event, Tim Nuttall said that antibiotic use “has consequences in terms of antimicrobial resistance and should only be used when justified”.
Speakers highlighted that effective management of otitis externa depends on identifying and addressing primary, predisposing, secondary and perpetuating factors, and on implementing a targeted two-phase treatment approach, comprising induction followed by long-term maintenance.
Routine dermatological assessment, including whole-skin examination, otoscopy and cytology, was emphasised as essential to identifying underlying causes and guiding treatment selection.
The role of the wider veterinary team, including trained veterinary nurses, and clear communication with dog owners were also recognised as key to improving outcomes in yeast-only otitis externa.
https://www.dechra.co.uk/products/dog/prescription/duotic
The 4D heart model, which can be viewed at: https://static.imascono.com/heartViewer, was designed in conjunction with Alejandro Suarez Bonnet, senior lecturer in comparative pathology at the RVC and consultant pathologist at The Francis Crick Institute.
The model demonstrates the structural changes in the mitral valve and associated heart chambers across stages A to D — from dogs at risk (stage A), through preclinical disease (stages B1 & B2), to symptomatic heart failure (stages C & D).
It has been designed to help pet owners understand the condition’s progression and support clearer communication of monitoring and treatment options.
Callum Watkins, brand manager at Dechra, said: “MMVD often catches dog owners unawares due to the silent early signs and the slow progressive nature of the condition.
“Our new 4D heart model will enable vets to clearly demonstrate the different stages of the disease, including the structural changes in the mitral valve and associated heart chambers, to aid discussions on the monitoring and treatment options.”
https://www.dechra.co.uk/companion-animal/internal-medicine/cardiovascular-disease.
The updated content includes instructions on interpreting blood test results and dosing with Felimazole (thiamazole), which is now available as both a tablet and a honey-flavoured oral solution.
The new Felimazole Oral Solution formulation is presented in a syringe graduated in 0.25 mg increments to ensure accurate dosing.
Thomas Johnson, Dechra companion animal brand manager said: “Consistent management and accurate treatment is key to enabling cats with feline hyperthyroidism to lead long and healthy lives.”
Dechra’s Endocrine app already covers Addison’s disease and canine Cushing’s syndrome. The inclusion of feline hyperthyroidism content aims to provide a single resource for veterinarians managing endocrine disorders in companion animals.
Dechra’s Endocrine app is available at the Apple App Store or Google Play Store
https://www.dechra.co.uk/products#/search=Felimazole
The range will include Vetoryl 20mg, 30mg and 60mg hydrolysed chicken flavoured tablets, which can be broken into halves or quarters.
The new Vetoryl tablets will come in packs of 30 tablets, although no word from Dechra as to when they'll arrive.
Thomas Johnson, Vetoryl brand manager at Dechra, said: “We are delighted that Vetoryl Flavoured Tablets for Dogs will soon be available, which will provide vets and pets owners with easy to administer, flavoured tablets to provide additional dosing flexibility.
"This, together with our commitment to providing extensive technical support and resources, will ensure that Vetoryl continues to be the UK’s leading licensed medical treatment for Cushing’s syndrome.”
The company says the webinar, presented by Dechra veterinary technical advisor, Emily Casey BVM&S MRCVS (pictured), will save vets' time and enhance their canine patients’ quality of life.
Emily said: “Canine Cushing’s syndrome can seem over-complicated, and we receive about 200 calls a month on the disease, so we’ve seen it all.
"Our new webinar will provide vets with a straightforward, no-nonsense approach to Cushing’s that will transform how they manage their next canine Cushing’s case.”
Delegates who join the webinar live will be entered into a prize draw to win a Littman Classic III Stethoscope.
https://go.dechra.co.uk/3-things-about-cushings
The survey, which takes about three minutes, will assess horse owners’ experiences of strangles and includes questions on the disease including preventative measures and vaccination.
There will be a prize draw from completed entries and the winner will get two VIP tickets to Your Horse Live 2025.
Rachel Harrison-Osborne MRCVS, equine field manager at Dechra said: “The strangles survey will provide us with a valuable insight into horse owners’ experiences of the disease and will enable us to identify any trends that may exist to help us support owners who wish to put in place preventative measures to help prevent strangles.”
https://forms.office.com/e/85gzEd7J7A
Photo: Redwings Horse Sanctuary
The five-minute survey includes questions on the number of otitis externa cases seen in practice, consultation times, common compliance issues, cytology uptake and client behaviour change frameworks.
Completed entries will be entered into a draw for a Fortnum & Mason hamper worth £100.
Charlotte Hill, brand manager at Dechra said: “The otitis externa in dogs survey will provide us with valuable insight into vets’ experiences of the condition.
"It will also allow us to identify any trends that may exist to help us improve how we as a profession approach otitis externa, while supporting owners when treating the condition which can be frustrating to manage.
https://forms.office.com/e/J7frrbL56A
The webinars will be available as live podcasts and will also be able to be viewed on demand on the Dechra Academy.
In the strangles webinar, Dave Rendle, Gayle Hallowell and Richard Newton will explore the current landscape of strangles control, focusing on the role of vaccination, testing and quarantine measures.
In the disease prevention webinar, Gayle Hallowell, Dave Rendle, Tamzin Furtado and others will give an insight into chronic disease management and preventative vaccination to improve uptake and optimise treatment outcomes.
Both webinars broadcast from 8pm GMT, with a live Q&A session from 8:45pm, finishing at 9:15pm GMT.
https://membership.elearning.vet/Dechra-equine-medicine-series.
The new presentation is honey-flavoured and is available in 30ml or 100ml bottles with a syringe for precise dosing.
It has a two-year shelf life and a broached shelf life of six months.
Dechra companion animal brand manager, Thomas Johnson, said: “The addition of Felimazole Oral to our product range will provide vets with the flexibility to prescribe Felimazole as either a tablet or oral solution to accommodate the preferences of both the cat and its owner.
"This, combined with our extensive endocrinology resources, will ensure that vets have all the necessary tools to support their feline hyperthyroid cases.”
https://www.dechra.co.uk/cushings-connect
https://www.dechra.co.uk/addisons-connect
https://www.dechra.co.uk/search?q=felimazole#/search=Felimazole
https://apps.apple.com/gb/app/dechra-endocrinology-app/id1660737534
The webinars will be presented by Professor Ian Ramsey, Ellen Behrend, Joezy Griffin, Professor Jill Maddison and Imogen Schofield.
They'll focus on the diagnosis, management and treatment of dogs with Cushing’s and will include information about Dechra’s predictor tool to help vets identify and progress suspected Cushingoid cases to a definitive diagnosis.
The webinars will also cover the importance of ongoing monitoring to optimise control of the syndrome and practical tips and tricks to help owners maximise compliance and optimise the quality of life of patients.
The full webinar schedule is as follows:
The webinar will be presented by Dr Abigail McGlennon from the Equine Infectious Disease Surveillance (EIDS) team at the University of Cambridge who will present data from the Surveillance of Equine Strangles (SES) network to provide a detailed overview of strangles diagnoses across the UK.
Abigail will explore recent trends in outbreak reports, the genetic makeup of recent circulating strains and transmission links between UK outbreaks.
By linking research from her own PhD work on S. equi genomics and transmission with preventative strategies, Abigail show how to suggest and implement evidence-based prevention measures to clients.
The webinar will also offer advice on ‘the ates’ preventative measures – vaccinate, isolate, investigate and communicate – and will include information on when horse owners should be vaccinating with Strangvac and an outbreak management vaccination plan using the traffic light ‘green, amber and red’ system.
https://go.dechra.co.uk/preventative_strategies_for_strangles
The sessions will take place in Gallery Suite 17 and are first come, first served.
Dechra will also be sponsoring two equine sessions at LVS:
www.dechra.co.uk/events
https://london.vetshow.com/
Furosoral contains furosemide and is indicated for the treatment of hydrothorax, hydropericardium, ascites and oedema, particularly in animals where these conditions are associated with cardiac insufficiency and renal dysfunction.
Furosoral replaces Dechra’s previous diuretic treatment, Frusedale.
It is available in both 10 mg and 40 mg double-divisable tablets.
The recommended daily starting dose for cats and dogs is 2.5 mg per kg of body weight.
Dechra says careful weighing is essential to ensure accurate dosing, but that the dosage can be doubled initially for severe or particularly resistant cases and adjusted to the lowest clinically effective dose for maintenance therapy if required.
Dechra companion animal brand manager, Charlotte Hill, said: “Furosoral offers a flexible treatment solution where dosage can be adjusted, depending on the needs of the patient and the underlying causes, to give vets more options for treating cats and dogs with fluid retention.
“To ensure it is as appealing to pet owners as it is to veterinary professionals, Furosoral is available in our innovative Smart Tab format, giving owners confidence that they are giving their dog or cat the right dosage and aiding compliance, leading to better outcomes for the animal.”
Furosoral 10 mg and 40 mg tablets are available in blister packs of 100 tablets for quick and easy dispensing. Divided tablets can be stored in the blister pack for up to three days, ensuring no waste.
https://www.dechra.co.uk/products/dog/prescription#/search=furosoral/.
Invetx specialises in developing protein-based therapeutics for chronic conditions in companion animals, with a focus on monoclonal antibodies (mAbs).
Dechra says these therapies have targeted modes of action and therefore are often more effective, provide an extended duration of activity and have fewer side effects, all of which help to extend and improve the quality of life for companion animals while decreasing the care burden for pet owners.
Jesper Nordengaard, Chief Executive Officer of Dechra, said: "I regard this acquisition as hugely important for Dechra, marking the start of a new chapter in our growth.
"It demonstrates our ambition to create further points of differentiation and relevance with veterinarians and pet owners alike, confidence in our ability to deliver highly innovative new products, and capacity to execute large scale transactions at speed."
Jesper added: “The half-life extension technology developed by Invetx allows for the generation of therapeutics that make treatment of chronic conditions far more convenient for pet owners and veterinarians through improved compliance.
"The pipeline of products currently being developed are all high value potential and will deepen our expertise in core therapeutic areas such as atopic dermatitis and osteoarthritis, allowing for synergistic product development, sales & marketing, and education efforts in the future.”
https://www.invetx.com
Available in packs of 56 (4 x 14 tablet blister packs), Lodisure tablets are divisible for accurate dosing.
The recommended starting dose is 0.125-0.25 mg amlodipine per kg bodyweight per day, which equates to half a tablet for cats weighing less than 4kg (and more than 2kg) and one tablet per day for cats weighing between 4kg and 8kg.
It can be administered directly to the cat or given with a small quantity of food.
Dechra companion animal brand manager, Sarah Musgrave, said: “Feline hypertension is very often part of a more complex diagnosis, therefore it is important that antihypertensive therapies are easy to dose and administer.
"Lodisure is a new, first-line, easy to dose and administer treatment to control systolic blood pressure in cats while the underlying primary cause is diagnosed and treated, which vets can rely on in their day-to-day practice.”
https://www.dechra.co.uk/products/cat/prescription/lodisure.
The ‘Ear essentials – a holistic approach to the treatment of canine otitis externa’ webinar will include a presentation by Jonathon Elgie, veterinary technical advisor at Dechra UK and Ireland.
Jonathon will talk delegates through case examples to help them make decisions that can be used in practice and take a clear, practical and holistic approach to treatment.
He will also update vet professionals on Dechra support including the Lifelong Ear Partnership which provides education, tips and assistance to achieve better clinical outcomes and owner satisfaction.
Across Europe, the company has over 30 technical experts who get over 2,500 technical calls each year about Cushing’s.
The company also publishes the Dechra Academy, which provides a range of free online courses for vets.
There's also Dechra’s endocrinology app which was developed using data from the Royal Veterinary College’s VetCompass database to help vets diagnose and manage the endocrine disorders Addison’s disease (hypoadrenocorticism) and Cushing’s syndrome.
For owners, Dechra publishes the 'Suspecting Cushing’s' website and has created the Cushing’s monitoring app to help simplify the management process, improve compliance with medication and increase engagement in the dog’s care.
Sarah Musgrave, companion animal brand manager at Dechra, said: “Dechra has extensive experience in endocrinology.
"Cushing’s can be a challenge to identify, diagnose and manage and our ‘They’ve got Cushing’s. You’ve got us’ initiative demonstrates the comprehensive support that we have available for both vets and dog owners to help ensure that dogs with Cushing’s live long and healthy lives.”
The free app is designed to help to track changes and improvements in a dog’s health during treatment.
The app uses questionnaires to monitor clinical signs and quality of life and includes reminders for when checkups with routine blood tests should be carried out, which Dechra says are recommended at 10 days, 4 weeks, 12 weeks and every 3 months thereafter.
The app also sends pet owners daily reminders to administer medication to their dog.
Sarah Musgrave, companion animal brand manager at Dechra, said: “Continuous and consistent monitoring is key to finding the right Vetoryl dose for a dog with Cushing’s and restoring its health.
"The new Cushing’s syndrome treatment and monitoring app is a useful tool to help owners quickly and easily record and track any medical and lifestyle changes in dogs being treated with Vetoryl, which can then be shared with their vet during check-ups.”
To download the app, search for 'Cushing's monitoring' on either Apple's App Store or the Google Play Store.
The webinars will include a presentation by Peter Geldhof, Professor of Molecular Veterinary Parasitology at Ghent University in Belgium, who will focus on the development of novel diagnostics and vaccines for parasitic infections in pigs, and share the results of some of his research and academic projects.
Tuesday: https://www2.dechra.com/l/877972/2023-05-11/2f43x8p
Thursday: https://www2.dechra.com/l/877972/2023-12-19/2f4ll1q
Pergocoat contains pergolide, a long-acting dopamine receptor agonist.
It is available in 0.5mg (off-white) and 1mg (yellow) tablets for accurate dosing without the need to split tablets.
The tablets are film-coated to mask the bitter taste of pergolide and create a barrier between the horse owner and the active ingredient.
Available in two different pack sizes containing 60 or 160 tablets, Pergocoat tablets are packaged in double layered blister packs to help minimise the risk of accidental ingestion.
Rachel Addison BVM&S MRCVS, equine field support manager at Dechra said: “Pergocoat is available in two convenient tablet sizes to achieve an optimal treatment response.
"Horses can be monitored and reviewed every four to six weeks until stabilisation or improvement of clinical signs is observed.”
https://www.dechra.co.uk/products/horse/prescription/pergocoat#Pergocoat-0-5mg-60-film-coated-tablets-for-horses.
The first, hosted by Sam Taylor, head of veterinary specialists at ISFM (International Society of Feline Medicine) is titled ‘Whetting the appetite: purr-fectly feeding your knowledge of feline inappetence and why early detection shouldn’t be overlooked’.
The session, which starts at 12:30pm on Tuesday 6th, will explore the importance of feline inappetence, how it goes overlooked by owners and practices alike and why it shouldn’t be underestimated.
In the second session, which starts at 12:30pm on Friday 9th, Libby Koytzoumis, veterinary technical advisor at Dechra (pictured), will talk about one of the most commonly diagnosed endocrine diseases in dogs, Cushing’s syndrome.
Libby's webinar, ‘Are you seeing these usual suspects in practice?’ will explore the common signs, routes to diagnosis and the effective treatment and monitoring of Cushing’s.
https://thewebinarvet.com/events/virtual-veterinary-congress-2024
Cyclofin contains two active ingredients: 200 mg/ml of the anti-inflammatory flunixin-meglumine (eq. to 33.2 mg/ml flunixin meglumine) and 300 mg/ml of the class D anti-infective, oxytetracycline (eq. to 323.5 mg/ml oxytetracycline trihydrate).
Dechra says Cylofin acts within 24-36 hours and has sustained anti-bacterial activity for five to six days following a single intramuscular injection.
Administration is deep intramuscular injection in cattle and Cyclofin has a 35-day withdrawal period and a memorable dose rate of 1 ml per 10 kg body weight.
Alana McGlade MRCVS, national sales manager at Dechra, said: “BRD is one of the most prevalent and costly diseases on farm and early administration of an effective and fast-acting NSAID/antibiotic combination treatment, such as Cyclofin, can help relieve discomfort and stress, alleviate pain and improve demeanour and food intake.”
Cyclofin is available in 100ml vials.
https://www.dechra.co.uk/products/livestock/prescription/cyclofin#Cyclofin-300mg-ml.